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creatinine, aspartate aminotransferase, alanine aminotrans-
ferase and CLcr from the time of initial administration up to 
prior to the start of second administration were considered.
Results Groups A, B and C had 8, 123 and 90 patients, 
respectively. The incidence of grade 2 thrombocytopaenia 
was significantly higher in group A as compared to that in 
groups B (P < 0.01) and C (P < 0.05). On multivariate anal-
ysis, only a CLcr of <45 mL/min was an independent risk 
factor for thrombocytopaenia of ≥grade 2.
Conclusion When administering a PEM-containing regi-
men, thrombocytopaenia of ≥grade 2 is more likely to 
develop in patients with a CLcr of <45 mL/min.
Keywords Pemetrexed · Renal dysfunction · 
Thrombocytopaenia · Non-small cell lung cancer · 
Malignant pleural mesothelioma
Introduction
The advent of new drugs and knowledge has revolutionised 
the treatment of lung cancer. Using epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors for EGFR gene 
mutation-positive lung cancer [1–5] and anaplastic lym-
phoma kinase (ALK) inhibitors for echinoderm microtubule-
associated protein-like 4-ALK translocation-positive lung 
cancer [6, 7] have improved overall survival (OS) in these 
patients. First-line treatment for stage IV lung cancer not 
associated with genetic mutations includes the combination 
of third-generation cytocidal antineoplastic preparations, 
such as irinotecan (CPT-11), paclitaxel (PTX), gemcitabine 
(GEM) and vinorelbine (VNR), with platinum-based prepa-
rations such as cisplatin (CDDP) and carboplatin (CBDCA) 
[8]. The specific regimens include CPT-11 + CDDP (IP) [9], 
PTX + CBDCA (TC) [10, 11], GEM + CDDP (GP) [12] 
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Methods We retrospectively reviewed 221 patients with 
lung cancer, malignant pleural mesothelioma or thymoma 
who received treatment with a PEM-containing regimen 
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on the basis of pre-treatment renal function: group A [cre-
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and VNR + CDDP (NP) [12]. In the four-arm cooperative 
study [12], these four regimens were comparable in terms of 
therapeutic efficacy. However, much variability was observed 
with respect to the side effects. In particular, GP therapy was 
associated with a lower incidence of neutropaenia of ≥grade 
3 and febrile neutropaenia (FN) when compared with the 
other regimens. Moreover, no treatment-related fatality was 
observed in patients who received GP. The GP regimen has 
since been considered the safest regimen among the four 
regimens. Furthermore, in the JMDB study [13] that com-
pared pemetrexed (PEM) + CDDP [treatment for non-small 
cell lung cancer (NSCLC)] with GP therapy, the former was 
associated with significantly longer OS in patients with non-
squamous NSCLC. Moreover, PEM + CDDP therapy was 
associated with a significantly lower incidence of neutropae-
nia, thrombocytopaenia of ≥grade 3 and FN, as compared 
to that associated with GP therapy. Based on these results, 
the National Comprehensive Cancer Network guidelines 
recommended PEM + CDDP therapy as the regimen with 
the highest efficacy and safety for EGFR mutation-negative 
and ALK translocation-negative stage IV non-squamous 
NSCLC [8].
However, in a phase I study [14], PEM (500 mg/m2) 
was shown to be well tolerated in patients with a glomeru-
lar filtration rate (GFR) >40 mL/min. Subsequently, in the 
JMDB study, PEM was administered to patients with a 
GFR of >45 mL/min, while those with a GFR of ≤40 mL/
min continued to be excluded. Owing to the lack of defini-
tive evidence on the efficacy and safety of PEM in the latter 
category of patients, PEM therapy is not recommended for 
such patients.
PEM plasma clearance is known to correlate with 
renal function [14]. Furthermore, patients with a GFR 
of ≤45 mL/min were shown to have a high incidence of 
PEM-induced severe neutropaenia [15, 16]. However, as 
shown in the JMDB study, PEM + CDDP was shown 
to have the highest efficacy and safety in patients with 
NSCLC. Moreover, other recent studies have also sug-
gested the efficacy of PEM monotherapy for NSCLC 
[17, 18].
Therefore, it is necessary to examine tolerance in 
patients with a GFR of ≤45 mL/min for lung cancer 
treatment. Currently, the safety of PEM-containing regi-
mens has not been established for patients with a GFR of 
≤45 mL/min, and as evaluation by prospective clinical tri-
als is not ethically permitted, it is relevant first to perform a 
preliminary retrospective study.
Therefore, we retrospectively analysed data on 
patients who had received a PEM-containing regimen at 
our hospital. The objective was to investigate the effect 




Patients treated with a PEM-containing regimen 
[PEM + CDDP; PEM + CDDP + bevacizumab (Bev); 
PEM + CBDCA; PEM + CBDCA + Bev; PEM + Bev; 
and PEM monotherapy] for lung cancer, malignant pleu-
ral mesothelioma or thymoma at Fujita Health University 
Hospital between 1 September 2009 and 31 August 2014 
were enroled in the study. Patients with renal dysfunction 
induced by other agents and patients for whom renal func-
tion could not be assessed prior to the start of PEM treat-
ment were excluded.
Investigations
Data were accessed from the electronic medical records 
available at Fujita Health University Hospital. Renal func-
tion investigated prior to the start of treatment was used 
for the categorisation of patients according to renal func-
tion: group A [patients with creatinine clearance (CLcr) of 
<45 mL/min], group B (CLcr 45–80 mL/min) and group 
C (CLcr ≥80 mL/min). CLcr was calculated from serum 
creatinine levels using the Cockcroft–Gault equation [19]. 
The standard method to measure serum creatinine levels is 
the Jaffe method. However, we used the enzyme method, 
which is commonly used in Japan, and calculated serum 
creatinine levels by adding 0.2 to the actual measured val-
ues [20, 21].
Data on baseline variables such as age, sex, body sur-
face area and the presence or absence of cancer metastasis 
and invasion prior to the start of treatment were obtained. 
Data on the following treatment parameters were obtained: 
initial dose of pemetrexed (mg/m2), initial dose of cispl-
atin (mg/m2), initial dose of carboplatin (mg/m2), co-
administration of oral folic acid tablets and vitamin B12 
(because they may help reduce PEM-induced side effects 
[22–24]) and/or use of non-steroidal anti-inflammatory 
drugs (NSAIDs) (which can exacerbate PEM-induced side 
effects [25, 26]).
Assessment
The lowest documented values of blood cell counts (leu-
cocyte, neutrophil, red blood cell and platelet counts), 
haemoglobin and CLcr and the highest levels of serum 
creatinine, aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were assessed on the basis of the 
National Cancer Institute—Common Terminology Crite-
ria for Adverse Events version 4.0 (NCI-CTCAE version 
4.0).
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Statistical analysis
Data on variables with normal distribution are expressed 
as mean ± standard deviation. Non-normally distributed 
variables are expressed as means with interquartile ranges. 
Between-group differences with respect to normally dis-
tributed variables (expressed as frequencies) were assessed 
using the one-way repeated measures analysis of variance 
(ANOVA) while non-normally distributed variables were 
compared using the Kruskal–Wallis test. Data expressed 
as percentages were assessed by Chi-square test. For mul-
tiple comparisons, Bonferroni correction was applied after 
performing a Chi-square test for two groups. Univariate 
analysis was performed to identify risk factors. Variables 
with a significance level of <20 % were included in the 
multivariate logistic regression model. Hosmer–Lemeshow 
statistical test was used to verify goodness of fit. Statistical 
analyses were performed using SPSS version 22.0 (IBM 
Corporation, Armonk, NY, USA). Between-group differ-
ences associated with a P value of <0.05 were considered 
statistically significant.
Ethics
The present study was conducted in compliance with the 
‘ethical guidelines for clinical research’. The study proto-
col was approved by the ‘Ethics committee for epidemio-
logical and clinical research’ at our hospital.
Results
Patients
The study population consisted of 221 subjects [group A 
(n = 8), group B (n = 123) and group C (n = 90)]. All subjects 
were administered both oral folic acid tablets and vitamin B12. 
A statistically significant difference was observed between 
the three groups with respect to age, treatment regimen, pem-
etrexed dose and concurrent use of NSAIDs (Table 1).
Regimen
Statistically significant differences were observed between 
the three groups in terms of the usage rate of the CDDP-
containing regimen. On multiple comparisons, the usage 
rate for group C was significantly higher than that for group 
A (P = 0.032) and tended to be higher than that for group B 
(P = 0.056). No difference was observed between groups A 
and B (P = 0.21). Furthermore, between-group differences 
were observed with respect to the usage rate of CBDCA-
containing regimen. On multiple comparisons, the usage 
rate for group A was significantly higher than that for group 
C (P = 0.0095) and tended to be higher than that for group 
B (P = 0.090). No difference was observed between groups 
B and C (P = 0.14). There was no difference between the 
three groups in terms of the usage rate of Bev-containing 
regimen (Table 2).
Table 1  Patient background (before chemotherapy)
CLcr creatinine clearance, PEM pemetrexed, CDDP cisplatin, CBDCA carboplatin, NSAIDs non-steroidal anti-inflammatory drugs
a P < 0.05 versus group A (Steel–Dwass test)
b P < 0.01 versus group A (Steel–Dwass test)
c P < 0.01 versus group B (Steel–Dwass test)








Age (years) 72.5 (70.5–75.3) 72.0 (67.0–76.0) 62.0 (57.0–68.8)a,c <0.001 (Kruskal–Wallis test)
Sex (male, female) 5, 3 79, 44 67, 23 0.363 (χ2 test)
CLcr (mL/min) 38.0 (33.7–41.3) 63.3 (55.4–73.3)b 94.3 (85.9–102.3)b,c <0.001 (Kruskal–Wallis test)
Cancer classification 0.827 (χ2 test)
 Primary tumour 4 69 48
 Metastasis or infiltration tumour 4 54 42
Chemotherapy regimen 0.026 (χ2 test)
 PEM monotherapy 1 26 17
 PEM + CDDP 0 36 41
 PEM + CDDP + Bev 0 2 1
 PEM + CBDCA 7 51 24
 PEM + CBDCA + Bev 0 8 7
Dosage of PEM (mg/m2) 432.7 ± 66.7 488.3 ± 16.8d 485.1 ± 25.3d <0.001 (one-way ANOVA)
NSAIDs 0 33 36 0.013 (χ2 test)
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Safety
When assessing the onset of adverse events in each group 
by grade, the incidence of grade 1 thrombocytopaenia was 
higher in group B as compared to that in group C, while 
for grade 2, the incidence was higher in group A as com-
pared to that in groups B and C. No significant associa-
tion of severe adverse events (≥grade 3) with leucocyte, 
neutrophil and red blood cell counts, haemoglobin levels 
(Table 3) and elevated AST and ALT was observed between 
the three groups (Table 4).
Risk factors
We examined potential risk factors for thrombocytopaenia 
of ≥grade 2. Univariate analysis revealed a significant dif-
ference for the three following factors: CLcr of <45 mL/
min, CDDP administration and CBDCA administration. 
In contrast, for other factors such as age, PEM dosage 
and NSAIDs administration, no significant difference was 
observed. On multivariate analysis of the three factors 
that exhibited a significance level of <20 % on univariate 
analysis, only a CLcr of <45 mL/min was an independent 
risk factor. The administration of platinum-based prepara-
tions was not found to be a risk factor (Table 5). Among 
the eight patients with a CLcr of <45 mL/min, none of 
the five patients who developed thrombocytopaenia of 
≥grade 2 exhibited a decrease in CLcr of >10 mL/min 
over that at the time of initiation of the second course of 
treatment.
Discussion
The safety of PEM-containing regimens in patients with 
a CLcr of <45 mL/min has yet to be established. In this 
study, administration of a PEM-containing regimen to 
patients with a CLcr of <45 mL/min was associated with 
a significantly higher incidence of thrombocytopaenia 
of ≥grade 2. Furthermore, the propensity of CBDCA to 
cause thrombocytopaenia is well known [27–29], and upon 
identification of risk factors for thrombocytopaenia of 
≥grade 2, we found a CLcr of <45 mL/min to be an inde-
pendent risk factor. In other words, CBDCA and other fac-
tors appeared to have had little effect. Moreover, although 
the dosage was low in group A, the onset of thrombocyto-
paenia of ≥grade 2 appeared not to be affected by PEM 
dosage. This suggests that renal function is a stronger cor-
relate of the onset of thrombocytopaenia in patients receiv-
ing PEM therapy. The incidence of other types of haema-
totoxicity (as evidenced by haematological results) and 
liver dysfunction also appeared to be unaffected by renal 
function.
On subgroup analysis, none of the patients with a CLcr 
of <45 mL/min who developed thrombocytopaenia of 
≥grade 2 showed a decrease in CLcr by ≥10 mL/min by 
the start of the second course. This supports the notion that 
a further decline in renal function did not affect the inci-
dence of thrombocytopaenia in the present study. Fall in 
platelet counts generally occurs 7–10 days after the ini-
tiation of anticancer therapy, and the period of platelet 
decrease is considered to be approximately 14 days. In the 
present study, the mean platelet nadir period was 13 days, 
which is consistent with earlier reports. Therefore, it may 
be inferred that the occurrence of thrombocytopaenia of 
≥grade 2 in patients with compromised renal function does 
not necessarily imply a specific mechanism, but only the 
incidence is increased.
Furthermore, in the present study, the incidence of 
haematotoxicity in patients with a CLcr of <45 mL/
min included neutropaenia of ≥grade 3 (37.5 %) and 
thrombocytopaenia of ≥grade 3 (12.5 %). A breakdown 
of treatment methods revealed that PEM + CBDCA 
therapy was used in 7 out of 8 patients. This result was 
not remarkably higher than those reported by Schuette 
et al. [30] who evaluated PEM + CBDCA therapy 
Table 2  Combination 
chemotherapy regimens 
containing pemetrexed










 No. of patient (%) 0 (0 %) 38 (30.9 %) 42 (46.7 %) 0.007 (χ2 test)
 Dosage (mg/m2) – 73.2 (71.9–74.0) 73.3 (72.4–74.4) 0.64 (Mann–Whitney U test)
CBDCA plus PEM
 No. of patient (%) 7 (87.5 %) 59 (48.0 %) 31 (34.4 %) 0.008 (χ2 test)
 Target AUC 4.68 ± 1.23 4.93 ± 0.77 5.15 ± 0.80 0.53 (one-way ANOVA)
Bev plus PEM
 No. of patient (%) 0 (0 %) 10 (8.1 %) 8 (8.9 %) 0.56 (χ2 test)
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(neutropaenia, 26.2 %; thrombocytopaenia, 16.9 %). 
Therefore, it is inferred that the incidence of haematotox-
icity in patients with a CLcr of <45 mL/min was within 
the permissible range.
With regard to patient background, a significant differ-
ence was observed between the groups in terms of age, type 
of chemotherapy regimen and use of NSAIDs. With regard 
to age, as groups were divided according to renal function, 
the fact that more elderly patients were included in groups 
A and B is consistent with earlier reports [31]. In group 
A, a CBDCA-combined regimen was most often used. In 
group C, a CDDP-combined regimen was most often used, 
which was assumed to be affected by the following facts: 
the CDDP dosage needs to be adjusted according to renal 
function [32] and because CDDP therapy has been found 
to cause renal dysfunction [33], it is difficult to use CDDP 
in patients who have pre-existing renal impairment prior to 
the start of chemotherapy. Moreover, multivariate analysis 
revealed that the three factors (age, type of chemotherapy 
regimen and use of NSAIDs) had little effect on the onset 
of thrombocytopaenia of ≥grade 2.
Table 3  Incidence of haematotoxicity by grade and study group
χ2 test with Bonferroni correction
a P < 0.01 versus group A
b P < 0.05 versus group A










 Grade 1 0 (0 %) 10 (8.1 %) 13 (14.4 %) 0.219
 Grade 2 2 (25.0 %) 36 (29.3 %) 19 (21.1 %) 0.362
 Grade 3 2 (25.0 %) 15 (12.2 %) 10 (11.1 %) 0.510
 Grade 4 0 (0 %) 0 (0 %) 2 (2.2 %) 0.237
Neutropaenia
 Grade 1 1 (12.5 %) 21 (17.1 %) 18 (20.0 %) 0.816
 Grade 2 2 (25.0 %) 29 (23.6 %) 21 (23.3 %) 0.988
 Grade 3 2 (25.0 %) 18 (14.6 %) 11 (12.2 %) 0.567
 Grade 4 1 (12.5 %) 7 (5.7 %) 5 (5.6 %) 0.718
Anaemia
 Grade 1 4 (50.0 %) 71 (57.7 %) 48 (53.3 %) 0.831
 Grade 2 1 (12.5 %) 20 (16.3 %) 20 (22.2 %) 0.528
 Grade 3 0 (0 %) 5 (4.1 %) 7 (7.8 %) 0.409
 Grade 4 0 (0 %) 0 (0 %) 0 (0 %) –
Thrombocytopaenia
 Grade 1 3 (37.5 %) 68 (55.3 %) 35 (38.9 %)c 0.037
 Grade 2 4 (50.0 %) 6 (4.9 %)a 7 (7.8 %)b <0.001
 Grade 3 1 (12.5 %) 8 (6.5 %) 2 (2.2 %) 0.214
 Grade 4 0 (0 %) 4 (3.3 %) 3 (3.3 %) 0.873
Table 4  Effect of chemotherapy on liver function







P value (χ2 test)
AST increased
 Grade 1 3 (37.5 %) 39 (31.7 %) 35 (38.9 %) 0.559
 Grade 2 0 (0 %) 5 (4.1 %) 4 (4.4 %) 0.852
 Grade 3 0 (0 %) 0 (0 %) 1 (1.1 %) 0.491
 Grade 4 0 (0 %) 0 (0 %) 0 (0 %) –
 ALT increased
 Grade 1 4 (50.0 %) 67 (54.5 %) 53 (58.9 %) 0.702
 Grade 2 1 (12.5 %) 4 (3.3 %) 8 (8.9 %) 0.172
 Grade 3 0 (0 %) 4 (3.3 %) 6 (6.7 %) 0.423
 Grade 4 0 (0 %) 0 (0 %) 0 (0 %) –
Table 5  Risk factors for 
thrombocytopaenia of ≥grade 2
Predictive ability of final model quantified using the Hosmer–Lemeshow statistical test for goodness of fit; 
P = 0.756
CI confidence interval, CLcr creatinine clearance; CDDP cisplatin, CBDCA carboplatin, Bev bevacizumab, 
PEM pemetrexed, NSAIDs non-steroidal anti-inflammatory drug
Univariate analysis Multivariate analysis
Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Age (years) 1.02 (0.98–1.06) 0.26
Male 1.01 (0.47–2.21) 0.97
CLcr < 45 mL/min 10.17 (2.31–44.77) 0.002 6.40 (1.41–29.10) 0.016
Metastasis or infiltration tumour 1.54 (0.75–3.18) 0.24
CDDP 0.25 (0.09–0.67) 0.006 0.56 (0.15–2.08) 0.39
CBDCA 3.96 (1.80–8.73) 0.001 2.47 (0.86–7.09) 0.093
Bev 0.29 (0.04–2.27) 0.24
Dosage of PEM (mg/m2) 1.00 (0.99–1.02) 0.93
NSAIDs 0.85 (0.39–1.89) 0.70
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Our results suggest the need for close monitoring of 
platelet counts in patients with a CLcr of <45 mL/min 
undergoing treatment with PEM-containing regimens.
The retrospective nature of this study is a key limita-
tion. Assessment of non-haematotoxicities that could not be 
evaluated on the basis of laboratory results should be fur-
ther studied. PEM therapy is not currently recommended 
in patients with a CLcr of <45 mL/min in Japan, which 
explains the small sample size of eight patients in group 
A. This is likely to have introduced a bias with respect to 
patient characteristics (Table 1). However, multivariate 
analysis ruled out all risk factors other than renal func-
tion. Therefore, we believe that the results of the present 
study are useful. Our results along with those of other ret-
rospective studies may help to determine the optimal dos-
age levels for patients with compromised renal function 
and may help improve the safety profile of PEM-containing 
regimens.
Considering the fact that renal function declines with 
age [31], along with a relatively higher incidence of 
NSCLC in elderly patients aged >70 years [34], it is imper-
ative to establish the safety of PEM-containing regimens 
for patients with renal dysfunction. When using PEM-
containing regimens in patients with renal dysfunction cor-
responding to a CLcr of <45 mL/min, attention should be 
given to the potential onset of thrombocytopaenia.
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